Back to Search Start Over

DYNLT1 gene expression is downregulated in whole blood of patients at different Huntington's disease stages.

Authors :
Rosseto SM
Alarcon TA
Rocha DMC
Ribeiro FM
Ferguson SSG
Martins-Silva C
Muniz MR
Costa PF
GuimarĂ£es DA
Pires RGW
Source :
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology [Neurol Sci] 2021 May; Vol. 42 (5), pp. 1963-1967. Date of Electronic Publication: 2020 Sep 29.
Publication Year :
2021

Abstract

Huntington's disease (HD) is a neurodegenerative disorder caused by a CAG nucleotide expansion, which encodes the amino acid glutamine, in the huntingtin gene. HD is characterized by motor, cognitive, and psychiatric dysfunctions. In a previous study, we showed by qPCR that some genes altered in an HD mouse model were also altered in blood of HD patients. These alterations were mainly with respect to the dynein family. Therefore, this study aimed to investigate whether dynein light chain Tctex type 1 (DYNLT1) is altered in HD patients and if there is a correlation between DYNLT1 gene expression changes and disease progression. We assessed the DYNLT1 gene expression in the blood of 19 HD patients and 20 healthy age-matched controls. Also, in 6 of these patients, we analyzed the DYNLT1 expression at two time points, 3 years apart. The DYNLT1 gene expression in the whole blood of HD patients was significantly downregulated and this difference was widened in later stages. These data suggest that DYNLT1 could emerge as a peripheral prognostic indicator in HD and, also, might be a target for potential intervention in the future.

Details

Language :
English
ISSN :
1590-3478
Volume :
42
Issue :
5
Database :
MEDLINE
Journal :
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Publication Type :
Academic Journal
Accession number :
32995988
Full Text :
https://doi.org/10.1007/s10072-020-04772-0